Ionis Pharma rises after US FDA approves genetic disorder drug

Shares of drugmaker Ionis Pharmaceuticals IONS.O rise 3.2% to $44.20

Company says the U.S. FDA has approved its drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder

It says the drug, Dawnzera, will be available in the U.S. in the coming days

The drug is approved to prevent symptoms of a rare genetic disease called hereditary angioedema (HAE) in adults and pediatric patients over 12 years old

HAE causes frequent attacks of severe swelling in various parts of the body, including the hands, feet, genitals and face

Including session moves, stock up 22.2% YTD